Phase III trial results of China's inactivated Covid-19 vaccines officially published

2021-05-27 04:13:11

According to Sinopharm, on May 26th, The Journal of the American Medical Association (JAMA, IF45.54) published an article by Sinopharm's China National Biotec Group Company Limited (CNBG) on "Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults".

The report summarizes and analyzes the results of Phase III clinical trials on the efficacy and safety of the inactivated SARS-CoV-2 vaccines of Beijing Institute of Biological Products (BIBP) and Wuhan Institute of Biological Products (WIBP), which are affiliated with CNBG, based on the results of Phase III clinical trials of China Biologics' inactivated vaccines.

inactivated vaccines covid vaccine Sinopharm China

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Tencent Holdings repurchased 3.93 million shares for HK$1.5 billion on January 7
                            2025-01-07

                                    Ireland recorded a 12.8 billion euro fiscal surplus last year due to the "Apple tax" ruling
                            2025-01-07

                                    Ministry of Industry and Information Technology: Promoting technical verification of 10G optical network and artificial intelligence integration
                            2025-01-07

                                    Tencent's major shareholder Prosus reduced its stake in Tencent Holdings from 24.01% to 23.99% on January 6.
                            2025-01-07

                                    U.S. chip stocks rose before the market opened, with Nvidia up 0.6%
                            2025-01-07